Year-ender 2025 view on Indian pharma achievements

2025 felt like a quiet reset for Indian pharma. Exports and policy support remained important, but the more meaningful shift was in what people focused on inside companies and hospitals, said Saransh Chaudhary, president, global critical care, Venus Remedies and chief executive, Venus Medicine Research Center in a personal view on the Indian pharmaceutical sector.

The questions moved from how much we produce to whether the medicines we make deliver reliable outcomes for patients, especially in infectious diseases where antimicrobial resistance is now part of daily practice.

Looking back, 2025 felt like an inflection point for Indian pharma in more ways than one. Yes, exports continued to grow and policy support stayed strong, but what stood out to me was a change in the questions people were asking. The conversation began to move from “how much can we make” to “does it truly work for patients, and can we prove it with good data.” Quality stopped being a checklist item and became the real differentiator.